瑞巴派特

Name: 瑞巴派特
Brand: 济南圣和化工有限公司

CAS 90098-04-7C19H15ClN2O4MW 370.8

济南圣和化工有限公司现供应医药中间体及原料药——瑞巴派特（CAS 90098-04-7），分子式 C19H15ClN2O4，分子量 370.8。本页理化参数仅供参考，实际常规纯度按批次COA提供(不公开发布)，以批次 COA 及订单确认为准，支持批量采购与长期供货协议。

产品概览

CAS号	90098-04-7
分子式	C19H15ClN2O4
分子量	370.8
LogP	2.4
纯度	按批次COA提供(不公开发布)
包装	按订单/批次确认(不公开发布)
应用领域	医药中间体及原料药
类别	医药中间体及原料药

应用领域

医药中间体及原料药

瑞巴派特在医药中间体及原料药领域使用广泛。采购前请确认纯度等级与包装形式，以批次 COA 为验收依据。

包装与储存

包装规格按订单/批次确认(不公开发布)

纯度规格按批次COA提供(不公开发布)

储存条件密封、阴凉干燥处保存

运输常规化工运输

样品可协商提供

交期现货/按订单安排

供货能力：瑞巴派特备有现货，包装形式为按订单/批次确认(不公开发布)。我们支持对公转账并开具增值税发票，山东省内可安排快速配送，省外按物流时效发货，具体请联系 info@591daili.com。

质量与文件

每批产品随货提供 COA（分析证书）；可按需提供 MSDS/技术数据表及第三方检测报告。纯度与包装以批次 COA 及订单确认为准。

关于供应商

作为化工原料供应服务商，济南圣和化工有限公司长期服务于化工贸易、食品添加、医药中间体、日化原料等行业的采购需求。除瑞巴派特外，您还可以在站内按 CAS 号或产品分类检索更多品类，获取规格与报价。

常见问题

瑞巴派特的 CAS 号是多少？

瑞巴派特的 CAS 号为 90098-04-7。

该产品的纯度和包装规格是什么？

常规纯度规格为按批次COA提供(不公开发布)，包装为按订单/批次确认(不公开发布)，随货提供 COA。

瑞巴派特有什么用途？

主要应用于医药中间体及原料药。

如何购买或获取报价？

请发送邮件至 info@591daili.com 或通过 WhatsApp 联系，注明产品名称、CAS 号与需求数量，一个工作日内回复报价。供应商：济南圣和化工有限公司。

PubChem 公开数据

Description

Rebamipide · CAS 90098-04-7 · C19H15ClN2O4. UNII LR583V32ZR.

Identification

CAS Registry Number	90098-04-7
PubChem CID	5042
Molecular formula	C19H15ClN2O4
IUPAC name	2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
UNII (FDA)	LR583V32ZR

Computed Descriptors

Molecular Weight	370.8
XLogP3	2.4
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	5
Exact Mass	370.0720347
Monoisotopic Mass	370.0720347
Topological Polar Surface Area	95.5
Heavy Atom Count	26
Formal Charge	0

Physical description & handling notes

183.65 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
190.92 Å² [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
165.9 Å² [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
191.95 Å² [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
185 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Regulatory Status

GHS notification summary	50% (1 / 2)

GHS Hazard Classification

GHS notification summary	50% (1 / 2)
Reported hazard statements	H301 (50%)

This chemical does not meet GHS hazard criteria for 50% (1 of 2) of reports.

H301 (50%): Toxic if swallowed [Danger Acute toxicity, oral]

Documented Uses

Take with or without food. Food does not impact the bioavailability of rebamipide.
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders

Synonyms

rebamipide; 90098-04-7; Proamipide; Mucosta; OPC-12759; Rebamipida; Rebator; Rebamipidum; 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; DTXSID8045937; OPC 12759; NSC-758955; LR583V32ZR; DTXCID6025937; 2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinon-4-yl)propionic acid; 2-[(4-chlorophenyl)formamido]-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid

Frequently Asked Questions

What are the CAS number and molecular formula of Rebamipide?

CAS 90098-04-7; molecular formula C19H15ClN2O4; molecular weight — g/mol.

What other names is Rebamipide known by?

rebamipide, 90098-04-7, Proamipide, Mucosta, OPC-12759, Rebamipida.

Is Rebamipide classified as hazardous?

50% of GHS notifications report no hazard classification (1 of 2).

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.